Vectory Therapeutics closes series A financing to advance vectorized antibody into clinic

Nov. 14, 2023

Vectory Therapeutics BV has closed a €129 million ($138 million) series A financing to advance its vectorized antibody programs in neurodegenerative diseases.

BioWorld Science Financings Neurology/psychiatric Antibody Series A

Today's news in brief

BioWorld

BioWorld briefs for Dec. 8, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 8, 2023.

‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

BioWorld

For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...

Off-target immune response from modified mRNA impacts future development

BioWorld

The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...

Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

BioWorld

Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...

Upgrade your daily dose of biopharma and medtech news

Vectory Therapeutics closes series A financing to advance vectorized antibody into clinic